The Science of HBV Cure Meeting

Published on 05/08/2022

30 May-2 June, 2022
Hybrid event-Singapour

ENYO Pharma and its collaborators were presenting the last results on Vonafexor’s effect in HBV at The Science of HBV Cure Meeting organized by Singapore Hepatology Conference.
“Antiviral effects of oral farnesoid X receptor agonist Vonafexor combined with pegylated interferon alpha2a in untreated patients with chronic hepatitis B”.

https://scienceofhbvcure.org/

Read next in 'Events'

• The 2024 international workshop on Alport syndrome
• ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
• 6th CKD Summit – Chronic Kidney Disease Drug Development
• ASN Kidney Week
• Alport Connect 2023, the annual Alport syndrome patient and family meeting in US